

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 January 2025 (23.01.2025)



(10) International Publication Number
WO 2025/016906 A1

(51) International Patent Classification:

<i>A61P 35/00</i> (2006.01)	<i>A61K 31/454</i> (2006.01)
<i>C07D 285/10</i> (2006.01)	<i>A61K 31/506</i> (2006.01)
<i>C07D 417/10</i> (2006.01)	<i>A61K 31/5025</i> (2006.01)
<i>C07D 487/04</i> (2006.01)	<i>C07D 417/14</i> (2006.01)
<i>A61K 31/433</i> (2006.01)	<i>C07D 471/04</i> (2006.01)
<i>A61K 31/4439</i> (2006.01)	<i>C07D 491/107</i> (2006.01)

(21) International Application Number:

PCT/EP2024/069828

(22) International Filing Date:

12 July 2024 (12.07.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

23185489.4	14 July 2023 (14.07.2023)	EP
24182972.0	19 June 2024 (19.06.2024)	EP

(71) Applicants: **KATHOLIEKE UNIVERSITEIT LEUVEN** [BE/BE]; KU Leuven R&D, Waaistraat 6 - box 5105, 3000 Leuven (BE). **UNIVERSITY OF ZURICH** [CH/CH]; Prorektorat Forschung, Rämistrasse 71, 8006 Zürich (CH).

(72) Inventors: **BOLAND, Sandro**; c/o CISTIM LEUVEN vzw, Wetenschapspark Arenberg, Bio-Incubator Geb 2, Gaston Geenslaan 2, 3001 Leuven (BE). **KATKEVICIUTE, Egle**; c/o University Hospital, Dept. of Gastroenterology and Hepatology, Rämistrasse 100, 8091 Zürich (CH). **KILONDA, Amuri**; c/o CISTIM LEUVEN vzw, Wetenschapspark Arenberg, Bio-Incubator Geb 2, Gaston Geenslaan 2, 3001 Leuven (BE). **LAMBIN, Dominique**; c/o CISTIM LEUVEN vzw, Wetenschapspark Arenberg, Bio-Incubator Geb 2, Gaston Geenslaan 2, 3001 Leuven (BE). **MARCHAND, Arnaud**; c/o CISTIM LEUVEN vzw, Wetenschapspark Arenberg, Bio-Incubator Geb 2, Gaston Geenslaan 2, 3001 Leuven (BE). **PERICOLLE, Vincent**; c/o CISTIM LEUVEN vzw, Wetenschapspark Arenberg, Bio-Incubator Geb 2, Gaston Geenslaan 2, 3001 Leuven (BE). **PERVOLARAKI, Kalliopi**; c/o CISTIM LEUVEN vzw, Wetenschapspark Arenberg, Bio-Incubator Geb 2, Gaston Geenslaan 2, 3001 Leuven (BE). **SCHARL, Michael**; c/o University Hospital, Dept. of Gastroenterolo-

gy and Hepatology, Rämistrasse 100, 8091 Zürich (CH). **SPALINGER, Marianne**; c/o University Hospital, Dept. of Gastroenterology and Hepatology, Rämistrasse 100, 8091 Zürich (CH). **VANHERCK, Jean-Christophe**; c/o CISTIM LEUVEN vzw, Wetenschapspark Arenberg, Bio-Incubator 2, Gaston Geenslaan 2, 3001 Leuven (BE). **VERSELE, Matthias**; c/o CISTIM LEUVEN vzw, Wetenschapspark Arenberg, Bio-Incubator 2, Gaston Geenslaan 2, 3001 Leuven (BE).

(74) Agent: **DE CLERCQ & PARTNERS**; Edgard Gevaert-dreef 10a, 9830 Sint-Martens-Latem (BE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASES

(57) Abstract: The present invention relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of PTPN2 and/or PTPN1, yet more in particular for the prevention or treatment of cancer or metabolic diseases. The present invention also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds as well as to said compositions or preparations for use as a medicine, more preferably for the prevention or treatment of diseases mediated by activity of PTPN2 and/or PTPN1, yet more in particular for the prevention or treatment of cancer or metabolic diseases. The present invention also relates to processes for the preparation of said compounds.



WO 2025/016906 A1